NEULANDLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourOperatingExpenses02Member NEULANDLAB2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2019-10-012019-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member NEULANDLAB2019-10-012019-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares NEULANDLAB 2019-04-01 2020-03-31 2020-01-16 INR Lakhs Third quarter Single segment Manufacturing of Active Pharmaceutical Ingredients 2019-10-01 2019-12-31 Unaudited Consolidated 2038437000.00 10224000.00 2048661000.00 1054499000.00 0.00 -18301000.00 310283000.00 56925000.00 78182000.00 410355000.00 1891943000.00 156718000.00 0.00 156718000.00 31601000.00 14013000.00 45614000.00 0.00 111104000.00 0.00 0.00 0.00 0.00 111104000.00 -2577000.00 108527000.00 0.00 0.00 0.00 0.00 129005000.00 10 8.66 8.66 0.00 0.00 8.66 8.66 1.The financial results for the quarter and nine months ended 31 December 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11 February 2020. n n2.The above consolidated financial results have been prepared in accordance with principles and procedures as set out in IND AS 110 on 'Consolidated financial statements notified under Section 133 of Companies Act. 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended. n n3.The operations of the Company are predominantly related to the manufacture of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . n n4.The Company has adopted IND AS 116 Leases effective 1 April 2019, as notified by the Ministry of Corporate Affairs (MCA) vide Companies (Indian Accounting Standard), Amendment Rules, 2109 using the modified retrospective method. The transition resulted in recognition of Right-of-Use asset & lease liability. The effect of this adoption is insignificant on the profit for the period. n n5.The Consolidated Financial Results include results of the following subsidiaries: n(a) Neuland Laboratories Inc., USA; n(b) Neuland Laboratories KK., Japan. n n6.In accordance with the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018 dated May 09, 2018 the company has prepared and published the quarterly consolidated financial results for the quarter and nine months ended 31 December, 2019. Thus, the quarterly financial results reported above for the quarter and nine months ended 31 December, 2018 were not subjected to limited review. n n7.The Government of India, on 20 September 2019, vide the Taxation laws (Amendement) Ordinance 2019, inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income Tax at reduced rates as per the provisions/conditions defined in the said section. The Company is in the process of evaluting its position with respect to the aforesaid option. n n8.The Board of Directors had at the meeting held on 11 February 2020, declared interim dividend of Rs.2/- per equity share of face value Rs.10/- each. n n9.The EPS for quarters and nine months has not been annualised. n n10.Previous period figures have been regrouped/rearranged wherever considered necessary to confirm to the current year presentation. Single segment 2019-04-01 2019-12-31 Unaudited Consolidated 5710689000.00 21097000.00 5731786000.00 3023700000.00 0.00 -82503000.00 905557000.00 145040000.00 236541000.00 1146206000.00 5374541000.00 357245000.00 0.00 357245000.00 84287000.00 17896000.00 102183000.00 0.00 255062000.00 0.00 0.00 0.00 0.00 255062000.00 -7847000.00 247215000.00 0.00 0.00 0.00 0.00 129005000.00 10 19.88 19.88 0.00 0.00 19.88 19.88 Manufacturing expenses 259791000.00 Other expenses 150564000.00 Manufacturing expenses 692500000.00 Other expenses 453706000.00